Clinical Trial Update: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of everolimus and letrozole in patients with recurrent hormone receptor-positive ovarian, fallopian tube, or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Ovarian Endometrioid Adenocarcinoma
• Ovarian Germ Cell Tumor
• Ovarian Seromucinous Carcinoma
• Ovarian Serous Cystadenocarcinoma
• Ovarian Serous Surface Papillary Adenocarcinoma
• Peritoneal Carcinoma
• Undifferentiated Ovarian Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Letrozole (letrozole)

Snippet

Sponsor: Mayo Clinic | Conditions: Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-31